PCN Insights, News, Videos, and More
News
12/28/2023
Patients who received deep transcranial magnetic stimulation (dTMS) for OCD showed a significant improvement in both OCD and depressive symptoms, according to a study published in the Journal of Affective Disorders.
Patients who received deep transcranial magnetic stimulation (dTMS) for OCD showed a significant improvement in both OCD and depressive symptoms, according to a study published in the Journal of Affective Disorders.
Patients who received deep...
12/28/2023
Psych Congress Network
News
12/24/2023
Seemingly contradictory findings from recent studies comparing intravenous (IV) ketamine with electroconvulsive therapy (ECT) in outpatients with treatment-resistant depression may have practicing clinicians feeling unsure about which...
Seemingly contradictory findings from recent studies comparing intravenous (IV) ketamine with electroconvulsive therapy (ECT) in outpatients with treatment-resistant depression may have practicing clinicians feeling unsure about which...
Seemingly contradictory findings...
12/24/2023
Psych Congress Network
News
12/20/2023
The intergenerational transmission of psychiatric conditions appears to be mostly attributable to broader psychopathology comorbidity than specific conditions, suggest study results.
The intergenerational transmission of psychiatric conditions appears to be mostly attributable to broader psychopathology comorbidity than specific conditions, suggest study results.
The intergenerational...
12/20/2023
Psych Congress Network
Q&As
12/19/2023
Featuring Daniel G. Amen, MD
Featuring Daniel G. Amen, MD
Daniel G. Amen, MD, discusses his 2023 Evolution of Psychotherapy session "The End of Mental Illness: Towards a New Paradigm for Psychiatry."
Daniel G. Amen, MD, discusses his 2023 Evolution of Psychotherapy session "The End of Mental Illness: Towards a New Paradigm for Psychiatry."
Daniel G. Amen, MD, discusses...
12/19/2023
Psychiatry & Behavioral Health
Videos
12/18/2023
Featuring Craig Chepke, MD, DFAPA
Featuring Craig Chepke, MD, DFAPA
...
Craig Chepke, MD, DFAPA, shares his thoughts on screening for, diagnosing, and treating ADHD via telehealth.
Craig Chepke, MD, DFAPA, shares his thoughts on screening for, diagnosing, and treating ADHD via telehealth.
Craig Chepke, MD, DFAPA, shares...
12/18/2023
Psych Congress Network
Videos
12/14/2023
Featuring Greg Mattingly, MD
Featuring Greg Mattingly, MD
Greg Mattingly, MD, gives exclusive updates from day 2 of the National Academy of Sciences Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development Workshop.
Greg Mattingly, MD, gives exclusive updates from day 2 of the National Academy of Sciences Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development Workshop.
Greg Mattingly, MD, gives...
12/14/2023
Psych Congress Network
Videos
12/14/2023
Join Dr Carbray as she dissects the efficacy landscape of certain medications, uncovers contraindications and considerations for certain populations, and why these drugs might not be the go-to choices as first-line mood stabilizers.
Join Dr Carbray as she dissects the efficacy landscape of certain medications, uncovers contraindications and considerations for certain populations, and why these drugs might not be the go-to choices as first-line mood stabilizers.
Join Dr Carbray as she dissects...
12/14/2023
Psych Congress Network
News
12/13/2023
Greg Mattingly, MD, Associate Professor, Washington University
Greg Mattingly, MD, Associate Profess...
Dr Greg Mattingly shares exclusive insights from the historic meeting addressing the Adult ADHD crisis that you do not want to miss.
Dr Greg Mattingly shares exclusive insights from the historic meeting addressing the Adult ADHD crisis that you do not want to miss.
Dr Greg Mattingly shares...
12/13/2023
Psych Congress Network
News
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
